• Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department
Main Menu
  • Home
  • About
  • Employers by Category
    • Agriculture
    • Automation
    • Cancer Research
    • Cloud Software
    • Contract Research
    • Diagnostics
    • Drug Discovery
    • Genetic Testing
    • Genomics
    • Healthcare Services
    • Human Longevity
    • Medical Devices
    • Medical Imaging
    • Other
    • Pharmaceuticals
    • Research Institutes
    • Software Development
    • Synthetic Biology
  • Educational Programs
    • Undergraduate Computational Biology/Bioinformatics Programs
    • Undergraduate Biostatistics Programs
    • Summer Programs for Undergrads
    • Graduate Computational Biology/Bioinformatics Programs
    • Graduate Biostatistics Programs
  • Our Department

Envisagenics

101 6th Avenue
New York, NY 10013
Drug Discovery
101 6th Avenue
New York, NY 10013
www.envisagenics.com

Description

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence.

We focuses on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.

Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

Source: https://www.linkedin.com/company/envisagenics

Company size: 11-50 employees

Connect

  • Twitter URL
  • LinkedIn URL

Contact Us

CMU Computational Biology Department
5000 Forbes Ave
Pittsburgh, PA 15213
(412) 268-4671
social@cbd.cmu.edu

Legal Info

Follow our Twitter list of companies!

My Tweets

Computational Biology Career Events

No upcoming events

Copyright © 2018 Carnegie Mellon University. All Rights Reserved

Login

Lost your password?